Vertex Pharmaceuticals Incorpor with ticker code (VRTX) now have 20 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 234 and 174 and has a mean target at 207.3. With the stocks previous close at 170.23 this would imply there is a potential upside of 21.8%. The 50 day moving average now sits at 176.46 and the 200 day MA is 178.03. The company has a market capitalisation of $43,415m. You can visit the company’s website by visiting: http://www.vrtx.com
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG, Arbor Biotechnologies, Inc., Moderna Therapeutics, Inc., Genomics plc, Merck KGaA, Darmstadt, Germany, and X-Chem, Inc., as well as Janssen Pharmaceuticals, Inc. and Merck KGaA. The company was founded in 1989 and is headquartered in Boston, Massachusetts.